Life Expectancy for Type 1 Diabetes: What to Expect
Learn why people with this condition live fewer years on average than the general population—and why this doesn’t have to be the case for you.
Related Articles
Transcriptomic profiling and machine learning reveal novel RNA signatures for enhanced molecular characterization of Hashimoto’s thyroiditis
Scientific Reports – Transcriptomic profiling and machine learning reveal novel RNA signatures for enhanced molecular characterization of Hashimoto’s thyroiditis
Welcome! You are invited to join a webinar: Diabetes 101: The Science of Diabetes and the Law. After registering, you will receive a confirmation email about joining the webinar.
Join the American Diabetes Association and learn about the science of diabetes as it relates to legal issues. The presentation will provide an overview of…
Welcome! You are invited to join a meeting: Using Automated Insulin Delivery Devices in Diabetes Management. After registering, you will receive a confirmation email about joining the meeting.
This workshop–designed for primary care professionals, endocrinologists and other members of the diabetes care team–will offer participants an opportunity to learn from health care professionals…
Type 1 Diabetes | ADA
Get all the information on type 1 diabetes you need to better help the people you treat.
Case Study Competition | American Diabetes Association
Sharpen your skills and earn points. It’s a fun way to test your knowledge through friendly competition with your peers. Learn something new and discover…
Call for Abstracts
There is no better place to share your research than ENDO, the Endocrine Society’s annual meeting. Submitting an abstract earns media coverage for your work,…
Become a Member | American Diabetes Association
Become a professional member of the American Diabetes Association® (ADA) to expand your knowledge, enhance your perspective, and grow your connections through exclusive opportunities and…
HOMA-IR May Predict Lung Disease, Emphysema
HOMA-IR z-scores were associated with increased risks for incident lung disease, interstitial lung abnormalities, and emphysema.
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
All tested survodutide doses were tolerated, and dose-dependently reduced bodyweight.
Abstracts | American Diabetes Association
Submit your abstract for consideration for the 84 th Scientific Sessions. The Scientific Sessions Meeting Planning Committee encourages submissions that are innovative, challenge current treatment…